Overview
- VALOR’s Phase 3 results, published Saturday in NEJM and presented at the AAD meeting, showed the 30 mg dose improved the mean Total Improvement Score by 15.3 points over placebo at Week 52.
- The 30 mg dose outperformed placebo on all nine key secondary endpoints, and nearly twice as many patients were able to taper background corticosteroids.
- Skin symptoms eased quickly, with an 18.9% greater share achieving itch remission by Week 4 and higher cutaneous remission at Week 52 for those with more severe skin disease.
- Safety trade-offs emerged, with serious infections reported in 10% on 30 mg versus 1% on placebo and more discontinuations on 30 mg, though most infections resolved with treatment.
- The trial enrolled 241 adults across 90 global sites and tested 30 mg, 15 mg, and placebo, and an open-label extension is ongoing to gather longer-term safety and real-world tapering data.